Influence of gender on outcomes after intra-arterial thrombolysis for acute ischemic stroke

Neurology

Volumn 66, Issue 11, 2006, Pages 1745-1746

  Shah, S H ^a,b   Liebeskind, D S ^a   Saver, J L ^a   Starkman, S ^a   Vinuela, F ^a   Duckwiler, G ^a   Jahan, R ^a   Kim, D ^a   Sanossian, N ^a   Vespa, P ^a   Ovbiagele, B ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES; URINARY PLASMINOGEN ACTIVATOR;

EID: 33745655965     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000218208.31305.84     Document Type: Article

References (10)

1. Bousser M. Stroke in women: the 1997 Paul Dudley White International Lecture. Circulation 1999;99:463-467.
2. Wyller T, Sodring KM, Sveen U, et al. Are there gender differences in functional outcome after stroke? Clin Rehabil 1997;11:171-179.
3. Kent D, Price LL, Ringleb P, et al. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005;36:62-65.
4. Savitz S, Schlaug G, Caplan L, et al. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke 2005;36:1447-1451.
5. Liebeskind DS, Laughton AL, Kim D, et al. Vessel size explains gender differences in response to intravenous thrombolysis for acute stroke. Stroke 2006;37:622.
6. Buck BH, Kim D, Saver JL, et al. The volume of middle cerebral artery thrombi: assessment by GRE MRI, gender differences, and relation to response to fibrinolytic therapy. Stroke 2006;37:648.
7. Kain K, Carter AM, Bamford JM, et al. Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. J Thromb Haemost 2003;1:390-392.
8. Kain K, Catto AJ, Carter AM, et al. Decreased fibrinolytic potential in south Asian women with ischaemic cerebrovascular disease. Br J Haematol 2001;114:155-161.
9. Brown D, Johnston KC, Wagner DP, et al. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147-150.
10. Wechsler LR, Roberts R, Furlan AJ. Factors influencing outcome and treatment effect in PROACT II. Stroke 2003;34:1224-1229.